Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share from the same period last year.